NTR: Tighter Fertilizer Markets And DOJ Probe Will Shape Balanced Outlook

The analyst price target for Nutrien has risen by CA$4.18. Analysts attribute this change to updated assumptions for slightly stronger revenue growth, higher profit margins, and a lower future P/E multiple, reflecting the recent wave of higher sector targets and tighter global fertilizer markets.

Analyst Commentary

Recent research on Nutrien shows an active debate around how much value to place on tighter fertilizer markets, evolving portfolio actions, and the durability of current pricing. Most firms are adjusting price targets higher, but not all are aligned on the medium term risk and reward.

Bullish Takeaways

• Bullish analysts point to tighter global fertilizer supply, including disruptions in the Middle East and the Strait of Hormuz, as support for stronger nitrogen pricing into at least the first half of 2026. They view this as positive for Nutrien's earnings power and valuation multiples.
• Several firms highlight company specific portfolio moves in areas like Phosphate, Trinidad nitrogen, and Brazil Retail as potential drivers of more stable earnings and stronger free cash flow. They see these factors as supportive of higher price targets.
• Some research points to favorable grower demand and expectations for higher potash and crop protection volumes. Analysts view this as helpful for execution against current outlooks.
• Bullish analysts also reference sector wide target increases across fertilizer equities. In their view, tighter markets and higher fertilizer prices justify richer trough P/E multiples for Nutrien and peers.

Bearish Takeaways

• Bearish analysts cite rising potash supply as a key risk. They argue that it may limit how long current nutrient pricing can hold, which tempers confidence in the durability of higher earnings assumptions.
• Some research emphasizes that the recent rally in fertilizer stocks is already significant relative to the near term earnings impact of elevated spot pricing. This is seen as suggesting less room for upside if pricing normalizes faster than expected.
• The UBS downgrade signals concern that, despite sector tailwinds, Nutrien's current valuation may already reflect much of the near term benefit from tighter markets and higher prices.
• Cautious analysts also question how long conflict related supply disruptions and higher oil prices can keep fertilizer chains tight. This adds uncertainty to medium term growth and cash flow trajectories.

What's in the News

• The U.S. Department of Justice is investigating whether Nutrien and several other fertilizer producers coordinated to raise fertilizer prices, according to a Bloomberg report citing people familiar with the matter (Bloomberg).
• Nutrien announced a new normal course issuer bid to repurchase up to 24,057,066 shares, equal to 5% of its issued share capital, over a 12 month period ending March 2, 2027, subject to Toronto Stock Exchange acceptance. All repurchased shares will be cancelled.
• The Board of Directors authorized a new share buyback plan on February 18, 2026, adding another tool for returning capital to shareholders over time.
• Between October 1, 2025 and February 17, 2026, Nutrien repurchased 3,638,192 shares for US$224m, bringing total repurchases under the February 19, 2025 program to 8,708,901 shares for US$519.69m.
• The Board declared a quarterly dividend of US$0.55 per share, payable April 16, 2026 to shareholders of record on March 31, 2026. This is described as an approximately 1% increase from the prior dividend and equates to an annualized US$2.20 per share.

Valuation Changes

• Fair Value: CA$101.07 to CA$105.25, a modest upward shift of about 4.1%.
• Discount Rate: 7.11% to 7.10%, a very small reduction in the rate used to discount future cash flows.
• Revenue Growth: 1.44% to 1.47%, a slight upward adjustment to the long term top line growth assumption.
• Net Profit Margin: 8.12% to 8.92%, a meaningful increase in expected profitability on each $ of revenue.
• Future P/E: 19.20x to 18.04x, indicating a lower multiple applied to projected earnings despite higher fair value.